Dynor 5 mg Tablet | Samm Care

Uses of Dynor: - Type 2 diabetes mellitus Type 2 DM Severe or life-threatening hyperglycaemia, severe liver or renal failure, type 1 diabetes, diabetic ketoacidosis with or without coma, patients with severe infection or trauma.

Sulfonylureas

Glibenclamide is an orally effective hypoglycaemic agent that reduces blood sugar concentration by stimulating secretion of endogenous insulin from the pancreatic β-cells. It stimulates the mobilization of endogenous insulin with a lower dosage and with few incidence of side effects that any available anti-diabetic. Hypoglycaemic action associated with short-term therapy appears to include reduction of basal hepatic glucose production and enhancement of peripheral insulin action at target sites.

How to use Glibenclamide: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Glibenclamide is to be taken with food. Administration: Should be taken with food. Take w/ breakfast or the 1st main meal of the day. Adult Dose: Oral Type 2 diabetes mellitus Adult: Initially, 2.5-5 mg daily, may increase wkly by increments of 2.5-15 mg daily. Doses >10 mg daily should be given in 2 divided doses. Max: 20 mg daily. Elderly: Initially, 1.25 mg daily. Hepatic impairment: Severe: Contraindicated. Child Dose: Safety and efficacy not established Renal Dose: Renal impairment: Severe: Contraindicated.

Serum levels may be reduced by colesevelam. May increase hypoglycaemic effect w/ MAOIs, chloramphenicol, fluoroquinolones (e.g. ciprofloxacin), probenecid, NSAIDs, ACE inhibitors, fluoxetine, disopyramide, clarithromycin, salicylates, sulfonamides, beta-blockers. Increased serum levels w/ antifungal antibiotics (e.g. miconazole, fluconazole). May decrease hypoglycaemic effect w/ nonthiazide (e.g. furosemide) and thiazide diuretics, corticosteroids, phenothiazines, thyroid agents, oestrogens, OC, phenytoin, nicotinic acid, sympathomimetic agents, rifampicin, Ca channel blockers, isoniazid. Potentially Fatal: May increase hepatotoxic effect of bosentan.

Severe or life-threatening hyperglycaemia, severe liver or renal failure, type 1 diabetes, diabetic ketoacidosis with or without coma, patients with severe infection or trauma.

Common - Hypoglycemia (low blood glucose level) - Nausea - Headache - Dizziness Hypoglycaemia; cholestatic jaundice; agranulocytosis; aplastic anaemia; haemolytic anaemia. Blood dyscrasias (reversible), liver dysfunction, GI symptoms, allergic skin reactions. Potentially Fatal: Prolonged hypoglycaemia seen in elderly or debilitated patients with hepatic or renal diseases.

There is no information on the use of Glibenclamide in human pregnancy but it has been in wide, general use for many years without apparent ill consequence. Animal studies have shown no hazard. It has not yet been established whether Glibenclamide is transferred to human milk. However, other sulphonylureas have been found in milk and there is no evidence to suggest that Glibenclamide differs from the group in this respect.

Precaution: Elderly; malnourished; mild to moderate renal and hepatic disorders. Impaired alertness. Avoid alcohol. Careful monitoring of blood-glucose concentration. Adrenocortical insufficiency. Changes in diet or prolonged exercise may also provoke hypoglycaemia. Increased risk of hypoglcaemia due to its long half-life. Avoid in severe hepatic impairment. Pregnancy, lactation. Lactation: Not known if crosses into breast milk; avoid use in nursing women

Symptoms: Hypoglycaemia. Management: Mild hypoglycaemic symptoms without loss of consciousness or neurologic findings may be treated with oral glucose and adjust drug dosage and/or meal patterns.

Should be stored in a dry place below 30˚ C.

Sulfonylureas

Glibenclamide lowers blood glucose concentration principally by stimulating secretion of endogenous insulin from the pancreatic beta-cells. Hypoglycaemic action associated w/ short-term therapy appears to include reduction of basal hepatic glucose production and enhancement of peripheral insulin action at target sites.

There is no information on the use of Glibenclamide in human pregnancy but it has been in wide, general use for many years without apparent ill consequence. Animal studies have shown no hazard. It has not yet been established whether Glibenclamide is transferred to human milk. However, other sulphonylureas have been found in milk and there is no evidence to suggest that Glibenclamide differs from the group in this respect.

Related Medicines

Save Medicine to Collection

Dynor 5 mg

Create New Collection